Thomas Richard Kassberg - Mar 1, 2025 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
CBO & EVP
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Mar 1, 2025
Transactions value $
-$275,582
Form type
4
Date filed
3/4/2025, 08:19 PM
Previous filing
Oct 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +18.4K +7.29% $0.00 271K Mar 1, 2025 Direct F1
transaction RARE Common Stock Sale -$254K -6.03K -2.22% $42.10 265K Mar 3, 2025 Direct F2, F3
transaction RARE Common Stock Tax liability -$21.8K -508 -0.19% $42.92 265K Mar 3, 2025 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
F2 Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F5 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.